"My impression from the CC was that these new phase-2 trials will be in second-line NSCLC because the second line is where Tarceva and Alimta are approved.
I do not think the initiation of these trials is any kind of red flag because combination therapy is to be expected in this disease setting. To the contrary, I think it’s a positive sign that PFE wants to aggressively expand into the second line now."
I agree with you and I had similar thoughts when listening to their C/C.
What's next?
Colon,Renal,Ovarian....
Just Kidding,
Praveen
Market Data 
Markets 
AI
